A Phase 1 interventional study of vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin in Advanced Cancer, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-04-22.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Carcinoma, Non-Small-Cell Lung.
Among the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung, this one is the 5th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2005, is one of 11 in phase 1, and was the 2nd registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →None of the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →
Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 9 · Phase 3 1
First in 2001; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 62 across 6,023 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 21 across the 19 interventional studies. Of the 18 that completed or were terminated, 11 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc: 14 open now, 26 under way, 18 of them phase 3. Of 65 finished, 49 (75%) have results posted.
Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, this one is the 69th largest by enrollment of the 88 interventional ones that give a count, is one of 2 that started in 2005, is one of 19 in phase 1, and was the 4th registered.
Merck & Co., Inc’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 91 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The purpose of this investigational study is to determine the safety and tolerability of oral suberoylanilide hydroxamic acid when administered in combination with standard doses of pemetrexed and cisplatin for the treatment of advanced solid tumors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
vorinostat (Suberoylanilide Hydroxamic Acid \[SAHA\])
Drug: vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin
Drug page: Vorinostat
Dose escalation study starting with vorinostat (Suberoylanilide Hydroxamic Acid \[SAHA\]) capsules 200 mg b.i.d. in combination with Pemetrexed and Cisplatin (see table for Reporting Groups).
Also known as: MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)
Maximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level
MTD was determined by the occurrence of DLTs during the first treatment cycle. DLT describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment. The dose level is equal to the MTD if \< 2 patients experience a DLT and is also the highest tolerated dose level in the cohort.
Time frame: Cycle 1 (21 days)
Safety and Tolerability as Measured by the Number of Participants With Disease Progression
Number of participants with disease progression (protocol-mandated reason for discontinuation). Disease progression was determined by the principle investigator.
Time frame: Any time during 8 cycle treatment period through 30 days after.
First Patient In = 29-Aug-05. Last Patient Last Visit = 03-Dec-07. Multicenter (4 Outpatient Clinics) in US.
| Milestone | Cohort A - Vorinostat BID + Pemetrexed + Cisplatin | Cohort B - Vorinostat QD + Pemetrexed + Cisplatin | Cohort C - Vorinostat BID + Pemetrexed | Cohort D - Vorinostat QD + Pemetrexed |
|---|---|---|---|---|
| Started | 13 | 9 | 14 | 16 |
| Completed | 3 | 3 | 2 | 3 |
| Not completed | 10 | 6 | 12 | 13 |
| Withdrew: Adverse event | 5 | 4 | 3 | 3 |
| Withdrew: Progressive disease | 4 | 1 | 9 | 10 |
| Withdrew: Received radiation on new therapy | 1 | 0 | 0 | 0 |
| Withdrew: > 14 day delay in therapy start | 0 | 1 | 0 | 0 |
MTD was determined by the occurrence of DLTs during the first treatment cycle. DLT describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment. The dose level is equal to the MTD if \< 2 patients experience a DLT and is also the highest tolerated dose level in the cohort.
| Participants | Dose Level A.1 | Dose Level A.2 | Dose Level B.1 | Dose Level B.2 | Dose Level C.1 | Dose Level C.2 | Dose Level C.3 | Dose Level D.1 | Dose Level D.2 |
|---|---|---|---|---|---|---|---|---|---|
| Number (#) of DLT | 1 | 3 | 0 | 2 | 1 | 0 | 0 | 1 | 2 |
| # Participants treated at a dose level <MTD | 0 | 0 | 0 | 0 | 7 | 4 | 0 | 0 | 0 |
| # Participants treated at a dose level =MTD | 6 | 0 | 3 | 0 | 0 | 0 | 3 | 9 | 0 |
| # Participants treated at a dose level >MTD | 0 | 7 | 0 | 6 | 0 | 0 | 0 | 0 | 7 |
Number of participants with disease progression (protocol-mandated reason for discontinuation). Disease progression was determined by the principle investigator.
| Participants | Cohort A - Vorinostat BID + Pemetrexed + Cisplatin | Cohort B - Vorinostat QD + Pemetrexed + Cisplatin | Cohort C - Vorinostat BID + Pemetrexed | Cohort D - Vorinostat QD + Pemetrexed |
|---|---|---|---|---|
| Safety and Tolerability as Measured by the Number of Participants With Disease Progression | 4 | 1 | 9 | 10 |
| Age Continuous(years) | Cohort A - Vorinostat BID + Pemetrexed + Cisplatin | Cohort B - Vorinostat QD + Pemetrexed + Cisplatin | Cohort C - Vorinostat BID + Pemetrexed | Cohort D - Vorinostat QD + Pemetrexed | Total |
|---|---|---|---|---|---|
| Mean | 60.52 (35 to 81) | 58.23 (31 to 74) | 60.09 (41 to 78) | 63.63 (39 to 81) | 61 (31 to 81) |
| Sex: Female, Male(Participants) | Cohort A - Vorinostat BID + Pemetrexed + Cisplatin | Cohort B - Vorinostat QD + Pemetrexed + Cisplatin | Cohort C - Vorinostat BID + Pemetrexed | Cohort D - Vorinostat QD + Pemetrexed | Total |
|---|---|---|---|---|---|
| Female | 4 | 5 | 7 | 8 | 24 |
| Male | 9 | 4 | 7 | 8 | 28 |
| Race/Ethnicity(participants) | Cohort A - Vorinostat BID + Pemetrexed + Cisplatin | Cohort B - Vorinostat QD + Pemetrexed + Cisplatin | Cohort C - Vorinostat BID + Pemetrexed | Cohort D - Vorinostat QD + Pemetrexed | Total |
|---|---|---|---|---|---|
| Asian | 0 | 0 | 0 | 1 | 1 |
| Black | 0 | 2 | 0 | 1 | 3 |
| European | 0 | 1 | 0 | 0 | 1 |
| Hispanic American | 1 | 0 | 0 | 2 | 3 |
| White | 12 | 6 | 14 | 12 | 44 |
No study locations are listed for this record.
The record gives a start of Aug 2005, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2009, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorinostat
Carcinoma, Non-Small-Cell Lung →